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Abstract
Background: Though the use of Low Molecular Weight Heparin (LMWH) in general is preferred due to its convenient 
and eliminates the need for activated Partial Thromboplastin Time ( aPTT) monitoring but Unfractionated Heparin (UFH) 
is still widely used in clinical setting due to its availability and low price. Besides UFH, the use of oral anticoagulant therapy 
with warfarin, has been the standard therapy for the prevention of thromboembolism in patients with AF. Our aim is to 
report a case of the resolution of left atrial thrombus in a patient with mitral stenosis.
Case Illustration:  A Case report of a female patient aged 54 years who admitted with a sudden neurological deficits 
and mitral stenosis with atrial fibrillation. Bedside transthoracal echocardiography (TTE) showed mobile thrombus which 
moved and obstructed the mitral valve during diastolic phase. Unfractionated heparin (UFH) was administered 3000 unit 
bolus intravenously and maintained with 600 unit per hour for five days and  warfarin 2 mg was initiated two days after the 
first UFH administration. TTE evaluation showed the resolution of LA thrombus.  
Conclusion: The administration of the combination of UFH and warfarin had successfully caused  resolution of  the LA 
thrombus and prevented the patient from surgical intervention. This case report indicated that Unfractionated Heparin and 
Warfarin were still the treatments option in LA thrombus patients with mitral stenosis and atrial fibrillation. 
(Indonesian J Cardiol. 2019;40:301-307)
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The highest incidence of left atrial (LA) thrombus is in patients with rheumatic mitral stenosis and atrial fibrillation. LA thrombi tend to form when there is stasis of blood flow 
in the left atrium (LA).  In general, low-velocity flow 
in the LA is associated with atrial enlargement, mitral 
valve disease, atrial fibrillation (AF).1 It is well known 
that AF, which causes LA thrombus that may produce 
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an embolism, is a common cause of an ischemic stroke, 
and that AF-related strokes are accompanied by severe 
neurological deficits, disability and high mortality.2 
 Unfractionated Heparin (UFH), traditionally the 
backbone of antithrombotic therapy, is a heterogeneous 
mucopolysaccharide on blood vessels. The major of UFH 
is on the interaction of antithrombin and thrombin 
(factor IIa), to inhibit the thrombin induced platelet 
aggregation that initiates acute coronary syndrome 
and venous thrombosis.3 Serial transesophageal 
echocardiography (TEE) has demonstrated the 
dissolution of intracardiac thrombi with anticoagulant 
therapy. Besides UFH, the use of oral anticoagulant 
therapy with warfarin, described as a vitamin K 
antagonist (VKA), has been the standard therapy 
for the prevention of thromboembolism in patients 
with AF.4,5  Novel oral anticoagulants (NOACs) were 
developed as an alternative to vitamin K antagonists and 
several studies have evaluated the ability of NOAC to 
decrease clotting as well as the risk of major bleeding in 
comparison to vitamin K antagonists, such as warfarin. 
They have a decreased risk of significant bleeding and 
other secondary adverse events.6 However there is no 
clear guidelines or consensus for the management of 
left atrial thrombus in rheumatic mitral stenosis with 
atrial fibrillation and acute ischemic stroke. If an LA/
LAA thrombus is detected on a TEE, current guidelines 
recommend vitamin K antagonist (VKA) treatment 
with a therapeutic international normalized ratio (INR) 
of 2.0 to 3.0 for at least 3 weeks and a follow-up TEE to 
ensure thrombus resolution prior to interventions 7.8
 This is a case report of a patient presented with acute 
stroke due to valvular atrial fibrillation due to mobile left 
atrial thrombus which resolved after UFH and warfarin 
administration.  
Case illustration
A female patient 54 years old, admitted to Emergency 
Department of Tarakan Hospital in Jakarta with a 
sudden onset of slurred speech and left sided hemiparesis 
accompanied with shortness of breath which worsened 
one day prior to admission accompanied with palpitation 
and feeling weakness. Fatigue during activity occurred 
for the last one week with orthopnea and abdominal 
discomfort. The patient had never had these complaints 
before. She was known as an active teacher for nearly 
thirty years. She had never taken any particular medicine 
or herbal substances. She was a married lady and had 
three children with previously normal deliveries.
 From physical examination, patient looked severely 
ill, clouding consciousness with blood pressure 110/ 
70 mmHg, the heart rate was 134 times per minute 
irregular, the respiratory rate was 30 times per minutes, 
and the temperature was 36.7 degree Celsius. 
 Conjunctiva palpebral anemic and scleral icteric 
were not found with the distension of jugular vein. 
The first heart sound increased in intensity with mid 
diastolic murmur III/6 at apex and irregular heartbeat. 
The lungs sound was vesicular with rales in both basal 
Figure 1. Echocardiography showing severe mitral stenosis 
Figure 2. The apical four chamber view showed LA thrombus 
“flying” in the center of the left atrium
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sides. The abdomen was soft with hepatomegaly and 
normal peristaltic. Both extremities were warm with 
pretibial edema. 
 The electrocardiography examination was atrial 
fibrillation with QRS rate was 144 beat per minutes, 
QRS axis was RAD, QRS duration was normal with 
RVH. 
The chest X ray looked cardiomegaly with CTR was 
70% with normal aortic and pulmonary segments, apex 
was downward with double contour appearance. The 
laboratory findings showed normal limits. 
 Bed side echocardiography revealed dilated left 
atrium, normal left ventricular function (LVEF = 
67%), reduced right ventricular function (TAPSE = 1.4 
cm), global normokinetic wall motion, mild calcified 
RCC and NCC of aortic valve with normal function, 
mitral valve looked dooming with Wilkins’score was 7 
(Valve Thickening = 2, Leaflet mobility = 1, valvular 
Calcification = 2, subvalvular thickening = 2) with 
mitral valve area was 0.7 cm2, mean mitral valve 
gradient was 8 mmHg, trivial tricuspid regurgitation 
and mild pulmonary regurgitation (Fifure 1) Mobile left 
atrial thrombus was found with diameter 20 x 35 mm 
(figure 2)  and sometimes obstructed the mitral valves 
area during diastolic phase (Figure  3 and 4).
 The patient was diagnosed as acute stroke with 
severe mitral stenosis - NYHA FC IV- with left atrial 
thrombus and atrial fibrillation rapid ventricular 
response. The treatment of this patient was bed rest – 
semifowler position with O2 3 l/ minutes, furosemide 
injection bolus 40 mg intravenously (iv), maintenance 
2 x 20 mg/ iv, digoxin 0.50 mg drips intravenously, 
continued with digoxin 0.25 mg orally, spironolactone 
25 mg, unfractionated heparin (UFH) with initial 
dose of 3000 unit bolus intravenously, and maintained 
intravenous drips with the dosage of 600 unit per hour 
for five days. Oral anti coagulation warfarin 2 mg was 
given two days after the first initiation of unfractionated 
heparin. Activated plasma thromboplastin time 
(aPTT) was monitored every six hours since the initial 
administration with normal range varied between 1.5 
to 1.7 times compared to the control value. She was 
consulted to the neurologist for further management and 
was administered with citicholin 2 x 1 gr intravenously, 
piracetam 3 x 3 gr intravenously, and atorvastatin 20 
mg orally. The patient was also consulted to the cardiac 
surgeon planned for mitral valve replacement and 
thrombus evacuation.
 While waiting for surgery, the patient showed 
improvement of the neurological status.  As the 
preparation to surgery, patient underwent coronary 
angiography with normal result. 
 After 5 days of UFH administration and 3 days 
treated with warfarin 2 mg, prothrombin time (PT) and 
the international normalized ratio (INR) were evaluated 
and showed expected target (INR 2.6). No complication 
such as bleeding or bruising occurred during the 
administration of both anticoagulant. No signs of 
neurological deficits showed during the administration 
of UFH and warfarin.   Echocardiography examination 
was performed for post anticoagulant treatment 
and showed severe mitral stenosis (figure 5). No LA 
Figure 3. Parasternal long axis view showed LA thrombus 
moved closer to stenosis mitral valve
Figure 4. The LA thrombus moved obstructing the mitral 
valve area during diastole phase
Indonesian J Cardiol ● Vol. 40, Issue 3 ● July - September 2019304
Indonesian Journal of Cardiology 
thrombus found instead of showing a reduced density 
of LASEC (Figure 6).
 The patient didn’t undergo surgical management 
and had continuous oral medical treatment instead. 
She had a regular control at the heart clinic with stable 
condition and was performed the transesophageal 
echocardiography (TEE) five months after the acute 
stroke attack. The TEE concluded that MS severe was 
found with Wilkins Score 7; LA SEC and left atrial 
appendage SEC (LAA SEC) was detected without any 
thrombus (figure 7). The patient had warfarin (INR 
target 2.5 -3) and other medications for another four 
weeks and TEE evaluation was performed because 
the patient was planned to undergo balloon mitral 
valvuloplasty (BMV) and successfully deserved good 
result.
Figure 5. Showing the measurement of mitral valve area and 
mitral valve gradient
Discussion
Valvular heart disease is associated with a high risk of 
thromboembolic events.9 The coexistence of atrial 
fibrillation and rheumatic mitral stenosis is associated 
with a higher risk of thromboembolism.10 The presence 
of left atrial appendage (LAA) thrombi is a common 
finding in rheumatic mitral stenosis.11 The majority of 
embolisms associated with atrial fibrillation are from 
the LAA.12  This LAA  has an anatomic structure very 
favorable for thrombus formation in patients with AF, 
who often experience limited contraction and stagnant 
blood flow. In fact, a review of published reports reveals 
that 90% of cardiothrombic events in patients with 
AF originate from the LA/LAA.13 Patient in this case 
presented with mitral stenosis which never experienced 
any complaints and had been complicating atrial 
fibrillation that forming LA thrombus and eventually 
had an acute stroke. 
 Thrombus formation occurs along a pathogenesis 
continuum that starts with SEC or ‘‘smoke’’ formation 
(erythrocyte rouleaux formation indicative of blood 
stasis), progresses to sludge formation (very dense 
smoke) and ends with complete thrombus formation.14 
Persistent SEC in the left atrium on TEE has been 
associated with later thrombus formation and systemic 
embolization. Sludge has an echocardiographic 
appearance that is more viscid than smoke but less dense 
than thrombus.15 The anatomic structure of the LAA 
and acquired enlargement and stretch of the left atrium 
or LAA in valvular and nonvalvular heart disease provide 
the milieu for blood stasis. Microscopic endocardial 
changes in the LAA have been reported in atrial 
fibrillation as compared with sinus rhythm and mitral 
stenosis as compared with mitral regurgitation. Edema, 
fibrinous transformation, and endothelial denudation 
have been described in the LA tissue in patients with 
atrial fibrillation and thromboembolism.16 Rheumatic 
valve diseases are an important cause of morbidity and 
mortality, particularly in developing and undeveloped 
countries.17. The slowdown of blood flow and stasis in 
Figure 5. Showing the measurement of mitral valve area and 
mitral valve gradient
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the left atrium associated with rheumatic mitral valve 
stenosis (RMVS) causes the formation of thrombus.18 
The resulting thrombus joins the systemic circulation 
from the left atrium and causes embolic complications, 
the most serious being in the cerebrovascular system. 
However, it is not possible to explain the development 
of left atrial (LA) thrombus in patients with MS, and 
the major embolic events seen in around 20% of these 
with only valvular obstruction. Rheumatic valve disease 
is an autoimmune inflammatory process triggered by 
group A streptococcal infection.  The inflammatory 
reaction continues subclinically and can lead to the 
progression of valvular damage.19.20.21 In addition to 
LA stasis, inflammation, oxidative stress, platelet size, 
and an increase in activation have been found to be 
associated with thrombus formation.22.23 In this case, 
the patient appeared with acute ischemic stroke due to 
cardiac emboli which is presumed to be caused by atrial 
fibrillation and rheumatic mitral stenosis. 
 Ercan et al. reported a huge left atrial appendage 
thrombus in a patient with atrial fibrillation which 
was successfully treated with the combination of 
acetylsalicylic acid, UFH and tirofiban.17 Musa Cakici et 
al reported a case of giant left atrial appendage thrombus 
due to atrial fibrillation which was successfully treated 
with the combination of acetylsalicylic acid, UFH, 
tirofiban and warfarin. The setting of their patient was 
heart failure and low ejection fraction (30%) with atrial 
fibrillation. Though there is no consensus on how to 
treat a giant thrombus with AF in guidelines, 23 but our 
patient was successfully treated with the combination 
of UFH and warfarin. The basic consideration of 
administrating unfractionated heparin in this case 
regarding the advantages of UFH compared with Low 
Molecular Weight Heparin (LMWH) are that the 
anticoagulant effect can be promptly discontinued by 
stopping the intravenous infusion and it has a wider 
spectrum of antithrombotic activity.3 On the other 
hand, ischemic stroke can be transformed to become 
hemorrhagic especially after thrombolytic therapy. The 
incidence of spontaneous hemorrhagic transformation 
(HT) ranges from 38% to 71% in autopsy studies and 
from 13% to 43% in CT studies, whereas the incidence 
of symptomatic HT is from 0.6% to 20%.24,25  Our 
patient in this case had an acute stroke which was 
triggered by atrial fibrillation and was administered with 
UFH infusion without any signs of hemorrhagic stroke. 
The aPTT monitoring showed that the target level was 
achieved. 
 Glycoprotein IIb/ IIIa receptor blockers may be 
considered as an alternative therapy for giant thrombus 
in LA or LAA and have been used during percutaneous 
coronary intervention with a lower rate of bleeding 
and there are two reports on the successful use of these 
agents in patients with mechanical valve thrombosis. 
Additionally, Yuce et.al reported that tirofiban was 
successfully used for the treatment of atrial septal 
defect occluder device thrombus in a patient with heart 
failure.26,27  However, there is no sufficient evidence for 
glycoprotein IIb/ IIIa  inhibitors in these conditions. 
Our patient was administered with UFH and warfarin 
that showed good result; thrombus was completely lysis 
and the patient was free from the signs of stroke and had 
been cancelled from  the surgical management for her 
LA thrombus.
 Yuechun Li et al has reported a case of a resolution of 
massive left atrial appendage thrombi with rivaroxaban 
before balloon mitral commissurotomy in severe mitral 
stenosis due to intolerable use of warfarin in their 
patient.9 However current guidelines include treatment 
with vitamin K antagonist therapy such as warfarin to 
dissolve LAA thrombus for patients with valvular atrial 
fibrillation. However, the use of vitamin K antagonist 
is limited because of frequent dose adjustment, slow 
onset of action, and monitoring of coagulation status.23 
Therefore in our case, UFH was administered prior to 
warfarin to enhance the efficacy in the resolution of the 
LA thrombus. 
Figure 7. No thrombus found at LAA instead of SEC after the 
administration of unfractionated heparin
Indonesian J Cardiol ● Vol. 40, Issue 3 ● July - September 2019306
Indonesian Journal of Cardiology 
Conclusion
This is a case of a patient presenting acute ischemic 
stroke with atrial fibrillation and severe mitral stenosis. 
Bed side transthoracal echocardiography (TTE) showed 
mobile left atrial thrombus which was resolved with the 
combination treatment of unfractionated heparin and 
warfarin and the patient showed speedy recovery and 
eventually underwent BMV with satisfactory result. 
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List of Abbreviations
AF : Atrial Fibrillation
APTT : Activated plasma thromboplastin time
BMV : Balloon mitral valvuloplasty
CTR : Cardiothorasic ratio
INR : International normalized ratio
 LA : Left atrium 
LAA : Left atrial appendage
LASEC : Left atrial spontaneous echo contrast
LMWH : Low Molecular Weight heparin 
LVEF : Left Ventricle ejection fraction
MS : Mitral stenosis
NCC : Non coronary cusp
NOACs : Novel oral anticoagulants
NYHA : New York Heart Association
PT : Prothrombin time
RAD : Right axis deviation 
RCC : Right coronary cusp
RVH : Right ventricle hypertrophy
SEC : Spontaneous echo contrast
TAPSE : Tricuspid annular plain systolic excursion
TEE: Transesophageal echocardiography
HT : Hemorrhagic transformation 
TTE : Transthoracal echocardiography 
UFH : Unfractionated heparin
VKA : Vitamin K antagonist
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